The agreement gives Novartis worldwide rights to an mRNA-encoded CD19×CD3 T-cell engager designed to deplete pathogenic B cells without manufacturing a conventional CAR-T therapy.
Key Takeaways
- Novartis licensed worldwide rights to Abogen Biosciences’ ABO2203 and secured options on additional RNA programs.
- Abogen will receive $575 million upfront, with up to approximately $7.2 billion in milestones across all included programs.
- ABO2203 uses lipid nanoparticle-delivered mRNA to produce a soluble CD19×CD3 T-cell engager inside the patient.
Data Snapshot
| Item | Details |
|---|---|
| Companies | Novartis / Abogen Biosciences |
| Lead asset | ABO2203 |
| Modality | mRNA-LNP encoding a CD19×CD3 T-cell engager |
| Primary focus | Refractory B-cell-mediated autoimmune diseases |
| Autoimmune development | Early Phase 1 |
| Oncology development | Phase 1 in B-cell non-Hodgkin lymphoma |
| Licensed territory | Worldwide |
| Upfront payment | $575 million (approximately ₩782 billion) |
| Potential milestones | Up to approximately $7.2 billion (approximately ₩9.8 trillion) |
| Additional terms | Options on other RNA programs and potential royalties |
What Happened
Novartis entered a licensing and option agreement with China-based Abogen Biosciences on October 2, 2026. The agreement gives Novartis exclusive worldwide rights to ABO2203 and options to license additional therapies developed through Abogen’s RNA platform.
Abogen will receive $575 million upfront and may receive up to approximately $7.2 billion if all program options are exercised and specified development, regulatory and commercial milestones are achieved. Abogen may also receive royalties on future sales. (Abogen licensing announcement)
The $7.8 billion headline value is not attributable to ABO2203 alone. It includes potential milestones linked to additional optioned RNA programs.
Fierce Biotech reported that the deal followed early evidence of B-cell depletion in autoimmune disease and additional clinical experience in B-cell lymphoma. (Fierce Biotech analysis)
How ABO2203 Works
ABO2203 is not an in vivo CAR-T therapy. It does not genetically reprogram T cells to express a chimeric antigen receptor.
ABO2203 contains messenger RNA packaged inside a lipid nanoparticle. After cellular uptake, the mRNA directs host cells to produce and secrete a soluble CD19×CD3 T-cell engager.
The resulting protein binds CD3 on T cells and CD19 on B cells. This molecular bridge activates existing T cells against CD19-positive B cells, producing deep B-cell depletion.
B-cell reconstitution dominated by transitional and naïve cells may support an immune-reset effect, but durable immune tolerance has not yet been established.
Early Clinical Evidence
The published autoimmune evidence involves three patients with refractory secondary immune thrombocytopenia.
ABO2203 produced rapid and complete peripheral B-cell depletion, sustained depletion in bone marrow and durable platelet recovery through six months of follow-up. Only Grade 1 or 2 adverse events were reported, with no cytokine release syndrome observed. (Cell study via PubMed)
Separately, company-reported Phase 1 data from nine patients with relapsed or refractory B-cell non-Hodgkin lymphoma showed dose-dependent responses without reported cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome or dose-limiting toxicities. Both datasets remain too small to establish comparative efficacy or long-term safety. (ABO2203 AACR 2026 results)
Competitive Landscape
No mRNA-encoded T-cell engager or in vivo CAR-T therapy is approved for autoimmune disease.
| Company | Candidate | Approach | Development status | Key distinction |
|---|---|---|---|---|
| Novartis / Abogen | ABO2203 | mRNA-encoded CD19×CD3 T-cell engager | Early Phase 1 | Produces a soluble engager in vivo |
| Cullinan Therapeutics | CLN-978 | Recombinant CD19×CD3 T-cell engager | Phase 1 | Subcutaneous premanufactured protein |
| Cabaletta Bio | Rese-cel | Autologous CD19 CAR-T | Phase 1/2; registrational cohorts advancing | Patient-specific manufacturing and lymphodepletion |
| Kyverna Therapeutics | Miv-cel (KYV-101) | Autologous CD19 CAR-T | Phase 1/2 | Single-infusion ex vivo cell therapy |
CLN-978 is the closest mechanistic competitor because it also connects CD19-positive B cells with CD3-positive T cells. The difference is that CLN-978 is administered as a manufactured protein, whereas ABO2203 delivers the mRNA instructions needed to produce the engager in vivo. (Cullinan clinical pipeline)
Rese-cel and miv-cel pursue the same broad goal of deep B-cell depletion but require ex vivo cell manufacturing and have different safety, durability and treatment-logistics profiles. (Cabaletta clinical update, Kyverna clinical update)
Why It Matters
ABO2203 attempts to occupy the space between recombinant T-cell engagers and CAR-T therapy.
Its mRNA-based design produced a flatter and more sustained T-cell engager exposure profile than a comparable recombinant protein in early studies. The approach may also avoid cell collection, individualized CAR-T manufacturing and direct genetic modification of T cells.
The key question is whether those practical advantages translate into durable disease control. Novartis must show that protein production is predictable across patients and that ABO2203 can deplete pathogenic B cells without excessive T-cell activation, infection or prolonged immune suppression.
BP View
The $575 million upfront payment shows that Novartis sees meaningful value in ABO2203’s early clinical evidence. The larger strategic value lies in gaining access to an RNA platform that could support additional in vivo protein therapies.
ABO2203’s differentiation is not simply B-cell depletion. CAR-T therapies and recombinant T-cell engagers can already achieve that goal. Its proposition is that a subcutaneous mRNA-LNP injection could deliver deep B-cell depletion through a more scalable and potentially more controllable treatment.
The current evidence provides proof of concept, not definitive clinical validation. ABO2203’s value will depend on whether larger studies confirm its safety and translate B-cell depletion into durable, treatment-free disease control.
Related Post
For another approach to generating immune-cell therapies directly inside the patient, read my previous analysis below.
J&J Takes a Profit Hit to Secure an In Vivo CAR-T Platform
About BP
Biopharma Perspective explains global biopharma news through clinical, scientific and competitive perspectives.
Have a question about ABO2203 or a different view of the mRNA T-cell engager strategy? Leave a comment below.
Leave a Reply